A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.
Advanced Non-squamous Cell Non-small Cell Lung Cancer
DRUG: Anlotinib hydrochloride capsule|DRUG: Carboplatin injection|DRUG: Pemetrexed disodium f Injection|DRUG: Placebo
Progression free survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 48 weeks
Overall response rate (ORR) assessed by Independent Review Committee (IRC), Percentage of subjects achieving complete response (CR) and partial response (PR) based on IRC., up to 48 weeks|Overall survival (OS), OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up., up to 48 weeks|Disease control rate（DCR）, Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 48 weeks|Disease of Response (DOR), DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment., up to 48 weeks
This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.